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Abstract: The trace element selenium (Se) occurs in the form of the amino acid selenocysteine 
in selenoproteins. Selenoproteins exerts multiple physiological effects in human health, many 
of which are related with regulation of reduction-oxidation processes. In fact, the selenoenzyme 
families of glutathione peroxidase (GPx) and thioredoxin reductase (TRx) display the ability 
to act as antioxidants, protecting cells from oxidative damage. Furthermore, another class of 
selenoproteins are the iodothyronine deiodinase enzymes (DIO), which catalyze the conver-
sion of thyroxine (T4) in triiodothyronine (T3), then exerting a ﬁ  ne tuned control on thyroid 
hormones metabolism. Several studies have investigated the potential positive effects of Se 
supplementation in thyroid diseases, characterized by increased levels of hydrogen peroxide 
and free radicals, like autoimmune chronic thyroiditis. These studies have supplied evidences 
indicating that Se supplementation, maximizing the antioxidant enzymes activity, may reduce 
the thyroid inﬂ  ammatory status. Then, it may be postulated that Se could play a therapeutical 
role in thyroid autoimmune diseases. Despite the fact that recent studies seem to be concordant 
about Se beneﬁ  cial effects in decreasing thyroid peroxidase antibodies (TPOAb) titers and 
ameliorating the ultrasound echogenicity pattern, several doubts have to be still clariﬁ  ed, before 
advising Se supplementation in chronic autoimmune thyroiditis.
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Introduction
The trace element selenium (Se) was discovered in 1817 by the Swedish chemist 
Berzelius. Two hundred years later, Se is well-known as an essential mineral of pivotal 
importance for the human health. It is established that Se displays antioxidant activ-
ity, antiinﬂ  ammatory chemopreventive, and antiviral characteristics (Rayman 2000). 
Its effect on human health is due to its presence within some proteins (Kryukov et al 
2003). Unlike other metal elements that interact with proteins in form of cofactors, Se 
becomes cotranslationally incorporated into polypeptide chain as part of the amino acid 
selenocysteine (Sec), also known as the 21th aminoacid (Gromer et al 2005). The group 
of proteins that contain Sec as an integral part of their polypeptide chain are deﬁ  ned as 
selenoproteins. Between the domains, 25 selenoprotein families have been identiﬁ  ed in 
humans (Castellano et al 2005). The human selenoproteome is composed of 17 seleno-
protein families, some with multiple genes having similar functions. These comprise 
glutathione peroxidase (GPx) (ﬁ  ve genes), thioredoxin reductase (TrxR) (three genes), 
and iodothyronine deiodinases (DIO) (three genes), which have been functionally 
characterized as having oxidoreductase functions (Kryukov et al 2003). The entry 
point of Se in animals is via plants, which absorb the element in its organic form 
from the soil, where its content varies between different areas. In plants, Se becomes 
converted to organic forms such as methylated low-molecular-weight Se compounds 
and the amino acid selenomethionine (SeMet) and Sec (Whanger 2002). Importantly, 
Se compounds have the capacity to redox cycle and are metabolized to more reduced 
states, which are thought to account for Se compounds being effective antioxidants. In 
fact, Sec is part of the catalytic group within selenoenzymes and is directly involved Biologics: Targets & Therapy 2008:2(2) 266
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in redox reactions (Zhong and Holmgren 2000). The effects 
of Se on the organism are concentration-dependent, ranging 
from an antioxidant activity in the nanomolar–micromolar 
range to potentially prooxidant at concentrations above 
what is required for maximal selenoprotein synthesis. At 
even higher concentrations, Se compounds may accumulate 
and redox cycle with intracellular thiols, inducing oxidative 
stress and cellular damage (Vinceti et al 2001). Se is essential 
for life, and there is no doubt that adequate amounts of this 
element are required for optimal human health. Many of its 
physiologic roles may be ascribable to its presence within 
selenoproteins. For example, one of the most important cel-
lular processes, DNA synthesis, depends on the presence of 
Se within the catalytic site of TrxR (Arner and Holmgren 
2000). Moderate Se deﬁ  ciency has been associated to many 
conditions, such as increased risk of cancer and infections, 
male infertility, increased thyreocytes damage, and serious 
neurological diseases, including Alzheimer’s and Parkinson’s 
(Rayman 2000). However, for some of these conditions, the 
evidence is rather scant, conﬂ  icting data have been published, 
and need further conﬁ  rmations. On the contrary, a pathologi-
cal condition that is certainly associated with Se deﬁ  ciency is 
Keshan disease, a potentially fatal form of cardiomyopathy; 
this disease is prevalent in children and is endemic in some 
areas of China characterized by extremely low levels of Se 
in the soil (Levander and Beck 1997). It is supposed that 
infection by Coxsackie B virus may trigger the onset of this 
disease. Notably, the condition is prevented or completely 
reversed by Se supplementation (Xia et al 2005). Another 
disease due to a combined deﬁ  ciency of Se and iodine is 
myxedematous cretinism which is characterized by mental 
and growth retardation (Vanderpas et al 1990). It is ascer-
tained that Se deﬁ  ciency causes a reduction in GPx and DIO 
enzymes activity, accumulation of hydrogen peroxide (H2O2) 
causing damage to the thyroid gland, and impaired thyroid 
hormone metabolism. Se supplementation in this condition 
must be administered after iodide levels have been restored, 
as Se increases the activity of DIO, leading to a further loss 
of iodide from the damaged thyroid (Zimmermann and 
Kohrle 2002).
In the United States, where dietary intakes are higher 
than in many other countries, the current recommenda-
tion is 55 μg/day. In the United Kingdom, however, Se 
intake is considerably lower, and the recommended dose is 
75 μg/day for men and 60 μg/day for women (Surai 2006). 
These recommendations were based on the plasma GPx 
optimal enzyme activity, however, a recent study indicates 
that higher Se intake is required to obtain full expression of 
selenoprotein P (SelP) (Xia et al 2005). Then, it is suggested 
that SelP may be a better indicator of Se nutritional status 
than GPx, and that the recommended dietary intake may 
need to be revised.
Even if a large body of studies has made available a vast 
information about Se, the precise molecular mechanisms 
behind its effects in physiologic and pathologic conditions 
remain unknown.
The best known and most 
important human selenoproteins
The most common form of Se in human proteins is Sec, which 
becomes cotranslationally incorporated within the growing 
polypeptide chain. However, selenium-containing proteins 
exists also in other forms, such as proteins that nonspeciﬁ  -
cally incorporate Se during translation, and selenium-binding 
proteins that bind Se as a cofactor. Only a few of the 25 identi-
ﬁ  ed mammalian selenoproteins have so far been functionally 
characterized. Most of these selenoproteins exhibit enzymatic 
redox function via Sec, which confers their catalytic and 
antioxidant activities (Castellano et al 2005).
Thioredoxin reductase
Thioredoxin reductase (TrxR) and NADPH constitute the 
thioredoxin system, a major cellular redox system pres-
ent in all living organisms (Arner and Holmgren 2000). 
Three mammalian TrxR selenoenzymes have been identi-
ﬁ  ed: the cytosolic enzyme (TrxR1), the mitochondrial 
enzyme (TrxR2), and a testis-speciﬁ  c enzyme thioredoxin-
gluthatione reductase (TrxR3) (Sun et al 1999, 2001). The 
Trx system plays a pivotal role in embryo development. 
Knockout mouse model for Trx gene (Txn) are not vital 
and homozygous mutants for TrxR1 die shortly after 
implantation as a result of failure to proliferate, suggest-
ing that TrxR is essential for early differentiation and 
morphogenesis (Matsui et al 1996; Jakupoglu et al 2005). 
The similar Txn knockout and TrxR1 homozygous mutants 
phenotypes are mostly likely explained by impaired DNA 
synthesis due to accumulation of oxidized, nonfunctional 
ribonucleotide reductase. These results conﬁ  rm that the 
TrxR system is absolutely required for development, and 
probably cell proliferation in vivo, and also emphasize 
the importance of the Sec residue for catalytic activity. 
As observed for the TrxR1, complete removal of mito-
chondrial TrxR2 causes embryonic death and homozygous 
mutant embryos show decreased hematopoiesis, increased 
apoptosis in the liver, and cardiac defects (Nonn et al 2003; 
Conrad et al 2004).Biologics: Targets & Therapy 2008:2(2) 267
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Glutathione peroxidases (GPx)
Glutathione peroxidases (GPx) was the ﬁ  rst mammalian 
protein shown to incorporate Se in the form of Sec into 
catalytic site and was supposed to be associated with the anti-
oxidant activity of Se. GPxs are recognized for catalyzing the 
reduction of hydrogen peroxide and organic hydroperoxides, 
thus protecting cells from oxidative damage. The importance 
of glutathione peroxidases and their potentially beneﬁ  cial 
role in critically ill patients concerns the mechanism of 
detoxiﬁ  cation of peroxides to their respective alcohols at the 
expense of glutathione. It seems that all of the glutathione 
peroxidase isoforms share the same catalytic mechanism, 
with a highly conserved sequence of selenocysteine, tryp-
tophan and glutamine (Aumann et al 1997; Brigelius-Flohe 
1999). The role of plasma GPx as an antioxidant enzyme is 
not fully understood. Although its preferred substrate, glu-
tathione, usually has a low plasma concentration, increased 
cellular oxidative stress can export oxidized glutathione to 
the plasma compartment, where a combination of gluta-
thione reductase and GPx can restore redox balance and 
either return reduced glutathione to the cell, or use it as a 
substrate for plasma GPx. Thus, Se can act as antioxidant 
when incorporated as selenoenzymes in the extracellualr 
space, the cell cytosol, in association with cell membranes, 
having the potential role to inﬂ  uence the immune processes 
(Arthur 2000). Localization and main function of the seven 
GPx isoenzymes are resumed in Table 1.
Iodothyronine deiodinases
Three differentially distributed Sec-containing 
oxidoreductases (DIO1, DIO2, DIO3) constitute the fam-
ily of iodothyronine deiodinases (DIO). They catalyze the 
activation (DIO1 and DIO2) and inactivation (DIO3) of the 
thyroid hormones thyroxine (T4), 3,5,3’- triodothyronine 
(T3), and reverse-3,5,3’-triiodothyronine (rT3) by removing 
distinct iodine moieties, as indicated in Figure 1 (Bianco 
and Kim 2006). Among their actions, thyroid hormones 
contribute to regulate the function of heart, metabolism, 
growth, are pivotal for the development of the fetal brain, 
and display multiple interactions with other hormonal sys-
tems. DIOs exhibit different localizations and function in 
human tissues (St Germain et al 2005). DIO1 is expressed 
mostly in the liver, kidney, thyroid, and pituitary; DIO2 in 
the thyroid, central nervous system, pituitary, and skeletal 
muscle; DIO3 is most prominently expressed in the pregnant 
uterus, placenta, embryonic liver, embryonic and neonatal 
brain, and neonatal skin. The three DIOs exert different 
actions as DIO1 plays a role in T3 production in the thyroid 
Table 1 Localization and function of glutathione peroxidase (Stawicki et al 2007)
Glutathione peroxidase 
isoenzyme
Localization Function
GPx 1 Liver, erytrocytes Important in severe oxidative stress. Role in viral 
infectious processes
GPx 2 Liver, gastrointestinal tract First line of defence against ingested organic 
hydroperoxides. Involvement in apoptosis, cellular 
proliferation
GPx 3 Plasma, intestine, breast milk, adrenal gland, 
pulmonary lavage ﬂ  uid, renal proximal 
tubules
Thought to have largely regulatory functions 
associated with oxidative stress and malignancy. 
Expression induced by hypoxia
GPx 4 Distributed in cytoplasm, nucleus and mito-
chondria. Expressed in testis, lung, heart, 
cerebellum. Essential structural component 
of the sperm’s midpiece
Antioxidant involved in protection of biomem-
branes. Reduces phospholipids hydroperoxides in 
cellular membranes. Involved in redox signalling 
and regulatory processes (apoptosis, inhibition of 
lipoxygenases). Required for sperm fertilization. 
Lack of GPx 4 is lethal at an early embyogenic 
stage
GPx 5 Epididymis Potentially serves a “backup” function for seleno-
cysteine containing GPx isoforms in sperm. Can 
be secreted or membrane-bound
GPx 6 Bowman’s gland, olfactory epithelium, 
embryonic tissues
Olfaction. Putative odorant metabolizing enzyme
GPx 7 Breast tissues Breast cancer defense against oxidative stress
Abbreviation: GPx, glutathione peroxidases.Biologics: Targets & Therapy 2008:2(2) 268
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gland and controls the circulating T3 levels, whereas DIO2 
and DIO3 are proposed to function in the local deiodination 
processes. Recent evidence indicates that DIO2 represents 
a major source of circulating T3 in euthyroid humans, 
whereas DIO1 contributes more substantially at high, 
thyrotoxic T4 levels, as seen in hyperthyroid patients. The 
presence of Sec appears to be absolutely required for DIO 
catalytic activity and thus it is not surprising that Se levels 
have a direct regulatory effect on the expression of DIOs 
(Bates et al 2000; Kohrle et al 2005). Among various sele-
noproteins, DIOs rank high in the hierarchy of Se supply 
during Se deﬁ  ciency, DIO1 expression being maintained 
or slightly increased in the thyroid gland. In the brain and 
placenta, DIO1 and DIO3 expression is maintained dur-
ing Se restriction, whereas DIO1 expression decreases in 
other tissues. The mechanisms of DIOs regulation by Se 
availability is not fully understood, nevertheless, it appears 
to be tissue- or organ-speciﬁ  c. Additional regulators of 
DIOs expression are T3 and thyrotropin (TSH) (which act 
in a feedback loop), and cyclic adenosine monophosphate 
(cAMP) (Koenig 2005). Experimental models with knock-
out transgenic mouse, provided evidence of the crucial roles 
exerted by DIOs. In particular, knockout mice for DIO1 
display abnormal concentrations of thyroid hormones and 
their metabolities, suggesting a role in preserving iodine 
store within the organism; DIO2 deficient mice have 
alterations in auditory function, thermogenesis, and brain 
development; DIO3 knockout models exhibit reduced 
viability, growth retardation, impaired fertility, reduced T3 
and increased T4 levels (St Germain et al 2005). There are 
not well documented diseases derived from primary DIOs 
deﬁ  ciency in humans. However, in 2005, mutations of Sec 
binding protein 2 have been identiﬁ  ed. The authors reported 
an inherited selenocysteine defect, caused by a homozy-
gous misense mutation of SBP2, which is an indispensable 
protein for selenoprotein synthesis, resulting in abnormali-
ties in the deiodinases and defective thyroid metabolism 
(Dumitrescu et al 2005). Several diseases with disturbed 
thyroid hormone metabolism and expression of DIOs are 
known. In Graves’ hyperthyroidism the increased levels of 
T3 are known to induce DIO1 expression at the transcrip-
tional level, which further contributes to the progression of 
the disease; on the other hand the use of propylthiouracil 
(PTU) inhibits DIO1 by binding to Sec residue, which repre-
sents a beneﬁ  t in the treatment of hyperthyroidism (Bianco 
et al 2002; Leonard and Rosenberg 2003). In hypothyroid-
ism, decreased DIO1 levels with a concomitant increased 
DIO2 activity may be observed, potentially to serve as a 
rescue mechanism to provide local levels of T3 (Bianco 
et al 2002). Combined Se and iodine deﬁ  ciency leads to 
the condition of myxedematous cretinism. Reduced DIOs 
and GPx activity are both supposed to play a central role 
for the development of this disease. The decreased GPx 
activity increase oxidative damage in the thyroid, while 
the reduced DIO concentration profoundly alters thyroid 
hormone metabolism (Kohrle et al 2005). The involvement 
of Se and selenoproteins in autoimmune thyroid diseases 
are discussed in a separate paragraph.
Other selenoproteins
Several others selenoproteins have been identiﬁ  ed, and 
their localizations and functions have been quite clearly 
Thyroxine Thyroxine (T4) (T4)
Triiodothyronine Triiodothyronine
(T3) (T3)
Diiodothyronine Diiodothyronine (T2) (T2)
reverse reverse- -
Triiodothyronine Triiodothyronine
(rT3) (rT3)
DIO 1  DIO 1 
DIO 2 DIO 2
DIO 1  DIO 1 
DIO 2 DIO 2
DIO 1  DIO 1 
DIO 3 DIO 3
DIO 1  DIO 1 
DIO 3 DIO 3
Figure 1 Metabolism of thyroid hormones by types 1, 2, and 3 deiodinases.Biologics: Targets & Therapy 2008:2(2) 269
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deﬁ  ned. They are involved in multiple processes that concern 
transport and delivery of Se, apoptosis, proliferation and 
cancer, muscle cells function, inﬂ  ammation, and oxidation 
(see Table 2). Furthermore, there are some others seleno-
proteins that have not been characterized (SelH, SelO, SelT, 
and SelV), and whose functions are thought to be related to 
redox processes (Castellano et al 2005).
Selenium and thyroid metabolism
The importance of Se for the thyroid function has been 
increasingly recognized and multiple laboratory experi-
ments, clinical trials, and epidemiologic data have progres-
sively revealed the relationships between Se, iodine, and 
thyroid hormones metabolism. Of interest, for example, is 
the condition of iodine deﬁ  ciency. This situation, which is 
associated with high TSH values, produce increased levels 
of H2O2 (Smyth 2003). The cytotoxic action on thyroid 
cells depends on both the formation of free radicals and 
the defence ability of antioxidative enzymes, the latter 
being impaired in a state of Se deficiency and altered 
selenoproteins activity (Ekholm and Bjorkman 1997). In 
order to accept electrons derived from oxidative reactions, 
the thyroid cells physiologically generate a large amount 
of H2O2 at the cell surface. The thyroid is thus a source 
of H2O2, a necessary substrate for thyroperoxidase (TPO) 
activity. The generation of H2O2 is the rate-limiting step 
in the thyroid hormone synthesis and is regulated by TSH 
action on an interacting second-messenger system (Kimura 
et al 1995). The production of H2O2 leads to the iodination 
of tyrosine residues and the coupling of iodinated tyrosines 
to thyroglobulin (Tg). It is known that the Tg iodination 
in vivo takes place on the external surface of the apical 
plasma membrane, where TPO is integrated and H2O2 is 
generated (Bjorkman and Erkhold 1995). H2O2 may easily 
cross the apical membrane to the luminal site where it reacts 
with TPO for the iodination of Tg. Then, when H2O2 is avail-
able, iodination may be catalyzed by TPO and controlled by 
GPx, which degrades H2O2. Excess H2O2 may diffuse into 
the cell, where it will promptly be attacked by GPx, TRx, 
and catalase, which is present in the peroxisomes (Corvilain 
et al 2000). Increased GPx activity reduces H2O2 availabil-
ity, whereas in conditions of Se deﬁ  ciency decreased GPx 
activity results in higher generation of H2O2 and increased 
TPO activity. Therefore, the expected activity of the GPx 
system plays a pivotal function in the iodination process, 
while, the intrathyroidal concentration of Se is important 
for GPx activity. The GPx and catalase antioxidant systems 
are protected by the antioxidant protein thiol-speciﬁ  c anti-
oxidant (TSA), which modulates H2O2-mediated responses. 
TSA is TSH-dependent regulated, although the effect of TSH 
on TSA gene expression at the transcriptional level remains 
unclear (Kim et al 2001).
Selenium and thyroid autoimmunity
Some interventional studies have tested the hypothesis that 
Se administration may have a beneﬁ  cial effect on autoim-
mune thyroiditis (AIT). It has recently been reported that 
in patients with AIT from an area in South Germany with 
borderline Se intake, 200 μg 3-month Se supplementation, 
in the form of selenite, signiﬁ  cantly reduced anti-TPOAb 
Table 2 Localizations and functions of selenoproteins other than GPx, DIO, and TrxR
Selenoproteins Localization  Function
Selenoprotein P  Secreted to plasma by liver  Contains 50% of plasma Se
  Expressed in all tissues  Transport and delivery of Se
   Heavy-metal  chelator
Selenoprotein 15  Brain, lung, testis, liver, thyroid,  Involved in glycoprotein folding
  kidney  Potential tumor-suppression function
Selenoprotein N  Expressed in all tissues  Plays a pivotal role in muscle tissues
Selenoprotein W  Muscles, heart, intestine, prostate,  Antioxidant function 
  esophagus, skin  Putative functional role 
    in muscle and brain
Selenophosphate   Expressed in all tissues  Essential component of the Sec
synthetase 2    biosynthesis machinery
Selenoprotein R  Expressed in all tissues  Repairing of oxidative damaged proteins
Selenoprotein M  Heart, lung, kidney, uterus, placenta,   Potential role in the brain (low levels are
  thyroid, brain  associated with Alzheimer’s disease)
Selenoprotein S  Expressed in all tissues  Link between type 2 diabetes, inﬂ  ammation, 
    and cardiovascular disease
Selenoprotein K  Heart, muscle, pancreas, liver, placenta  Antioxidant function in the heart
Abbreviation: Se, selenium.Biologics: Targets & Therapy 2008:2(2) 270
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concentration and improved ultrasound echomorphology 
(Gärtner et al 2002). In a 6-month follow-up crossover study, 
the anti-TPO concentrations continued to decrease signiﬁ  -
cantly in the group that received Se, whereas the anti-TPOAb 
titers significantly increased in the group that stopped 
taking Se (Gärtner and Gasnier 2003). These ﬁ  ndings are 
supported by another study conducted in patients with AIT 
in a non-Se-deﬁ  cient area in Greece, in which anti-TPOAb 
concentrations also signiﬁ  cantly decreased with a combined 
treatment over 6 months of 200 μg of selenomethionine 
and LT4 (Duntas et al 2003). Anti-TPOAb reduction was 
prominent in the ﬁ  rst 3 months of treatment, which may be 
the result of elevated intrathyroidal Se levels achieved during 
the study with consequent enhancement of the scavenging 
activity of both the GPx and TRx systems. In this respect, 
supplemented Se protected against goiter and thyroid tis-
sue damage in a study from France that included 792 men 
and 1108 women from the SU.VIMAX study (Derumeaux 
et al 2003). The authors also found a relationship to thyroid 
echostructure and concluded that Se may protect against 
autoimmune thyroid disease. Another recent study from 
Greece, evaluated the effects of Se supplementation (200 
μg/day) in patients suffering from AIT. After 6 months of 
treatment a 9.9% reduction of TPOAb titers was observed; 
afterwards, while in one group the Se supplementation was 
continued, and a further decrement of TPOAb was observed, 
in the other group which stopped supplementation, a 4.8% 
increase took place (Mazopakis et al 2007). It has also 
been suggested that Se administration may have a protec-
tive role in pregnant women with AIT who are at a higher 
risk of miscarriage, as women with pregnancy loss had 
signiﬁ  cantly lower Se hair content than controls (Al Kunani 
et al 2001; Prummel and Wiersinga 2004). A particularly 
interesting patients in the ﬁ  eld of AIT, is represented by 
pregnant women. These patients are characterized by an 
increased risk of miscarriage, preterm delivery, and devel-
opment of thyroid dysfunction after delivery (Negro et al 
2006). One study, involving 2143 euthyroid pregnant women 
(7.9% of them with TPOAb), evaluated the effects of 200 μg 
of selenomethionine supplementation during and after preg-
nancy. Results showed that, in women with autoimmune 
chronic thyroiditis, post-partum thyroid dysfunction and 
permanent hypothyroidism were lower in the treated group 
in respect to the untreated group (28.6 vs. 48.6%, P  0.01; 
and 11.7 vs. 20.3%, P  0.01, respectively) (Negro et al 
2007) (Figure 2). The same study demonstrated that the Se 
supplemented women displayed lower TPOAb titers during 
the postpartum period and better thyroid ultrasound patterns 
when compared with the untreated ones. Finally, Moncayo 
and Moncayo (2005) reported in a paper published in 2005 
few cases of patients with autoimmune hypothyroidism 
who beneﬁ  ted from a daily Se supplementation. The cited 
Figure 2 Percentage of patients who had PPTD (left) and hypothyroidism (right) develop in TPOAb(+) women who received Se (group S1) or placebo (group S0), and in TPOAb(-) 
women (group C). , P  0.01 copyright © 2007.   The Endocrine Society. Reproduced with permission from Negro R, Greco G, Mangieri T, et al. 2007. The inﬂ  uence of selenium 
supplementation on postpartum thyroid status in pregnant women with thyroid peroxidase autoantibodies. J Clin Endocrinol Metab, 92:1263–8.
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patients, having serum Se concentrations below the lower 
limit, had an extraordinary recovery of thyroid function after 
Se treatment, with a condition of restored euthyroidism and 
an ameliorated ultrasound echogenicity pattern (Moncayo 
and Moncayo 2005).
Despite their different phenotypes, Hashimoto’s 
thyroiditis and Graves’ disease (GD), share the produc-
tion of organ-speciﬁ  c antibodies, and a common genetic 
background (Dayan and Daniels 1996; Strieder et al 2003; 
Caturegli et al 2007). GD is characterized by a condition 
of increased oxidative stress, not only in the acute phase of 
the disease, but also in the state of euthyroidism, induced 
by anti-thyroid medications (Ademog ˘lu et al 2006). In 
fact, several studies outlined the association of GD with 
impaired antioxidant activity. Urinary malondialdehyde 
levels, a marker of oxidative stress, is higher in hyperthy-
roid patients compared to euthyroid controls (Guerra et al 
2005). In patients suffering from GD, the use of antithyroid 
drugs, either methimazole or propylthouracil, have been 
proven to be effective in lowering oxidant generation and 
improving the imbalance of the antioxidant/oxidant status 
(Seven et al 2001; Abalovich et al 2003). A recent study 
by Wertenbruch and colleagues (2007) compared serum Se 
levels in patients with remission and relapse of GD. The 
authors found that highest serum Se levels (120 microg/
l) were seen in the remission group, indicating a positive 
effect of Se levels on the outcome of GD. In addition, the 
authors showed that TSH-receptor antibodies levels and 
serum Se values were positively correlated in the relapse 
group, whereas a negative correlation of both parameters 
were seen in the remission group, supporting the idea of 
a positive effect of Se on thyroidal autoimmune process 
(Wertenbruch et al 2007). One study from Croatia, evalu-
ated the effects of supplementation with a ﬁ  xed combina-
tion of antioxidants (vitamins C and E, beta-carotene and 
selenium) on superoxide dismutase activity, copper and 
zinc concentrations, and total antioxidant status in eryth-
rocytes derived from a group of patients with GD treated 
with methimazole, with respect to the rate of achieving 
euthyroidism (Bacic-Vrca et al 2005). Results showed that 
patients receiving antioxidant supplementation along with 
methimazole therapy achieved euthyroidism at a faster rate 
than those treated with methimazole alone. The activity of 
superoxide dismutase similarly decreased in both groups, 
while the total antioxidant status was mostly improved in the 
supplemented group. Taking together, the abovementioned 
studies’ results, may lead to think that Se supplementation 
may exert a beneﬁ  cial effect on the course of GD.
Conclusion
Se is a mineral of pivotal importance for human health. 
It is an integral part of selenoproteins, many of which are 
involved in redox processes and are effective as antioxidants. 
The most frequent disease involving the thyroid gland is the 
autoimmune chronic thyroiditis, an inﬂ  ammatory process 
which progressively destroy the gland. Several studies 
have examined the potential beneﬁ  ts of Se in this disease to 
assess if its supplementation may be effective in increasing 
the antioxidant defences. These studies have by consent 
demonstrated that Se supplementation, probably maximiz-
ing the Se-dependent enzymes activity, is able to reduce the 
inﬂ  ammatory state, exerting a decline of TPOAb titers and 
an amelioration of the ultrasound pattern. Furthermore, there 
are some preliminary data which indicate a possible role of 
Se supplementation in ameliorating the course of GD, even 
if speciﬁ  cally and well-designed randomized controlled trials 
are necessary to address this issue.
However, several points have to be still clariﬁ  ed. Firstly, 
we have not fully understood functions and actions of the 
already identiﬁ  ed selenoproteins; then, the ﬁ  rst question is 
whether the effect of Se on thyroid autoimmunity depends 
on the maximization of GPx activity alone or also of other 
selenoproteins. Secondly, it has still to be deﬁ  ned the exact 
amount of Se to be given to maximize the enzymatic antioxi-
dant activity. Thirdly, a cost/beneﬁ  t evaluation is mandatory; 
in fact, the ﬁ  nal result of autoimmune chronic thyroiditis is 
represented by hypothyroidism; Se supplementation should 
delay the time of Levothyroxine initiation, but obliges in 
any case the patient to take a tablet a day, and even when 
hypothyroidism develops, substitutive treatment with Levo-
thyroxine has no side effects and it is a very cheap drug. One 
viable application of Se, may be its supplementation during 
pregnancy (possibly in conjunction with iodine supplementa-
tion). In fact, by now, screening for thyroid function during 
pregnancy is not warranted (Abalovich et al 2007). Consid-
ering that up to ~10% of pregnant women are positive for 
TPOAb, and that about 8% of all pregnant women develop 
postpartum thyroiditis, it is plausible a positive effect exerted 
by Se in this particular kind of patients (Poppe and Glinoer 
2003; Stagnaro-Green 2004). Finally, it has to be reminded 
that Se have had a putative role in preventing atherosclerosis 
and carcinogenesis, and a possible action in improving 
glucose metabolism. All these hypothesis have been proven 
to be wrong, and in addition, a recently published study 
even suspected Se to be responsible for increased risk of 
developing diabetes (Hunter et al 1990; Garland et al 1995; 
Bleys et al 2006; Stranges et al 2007).Biologics: Targets & Therapy 2008:2(2) 272
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